1ª edição – Especial Simpósio

Trastuzumab-Emantasin Conjugate is standard for patients with HER2-positive breast cancer and residual disease

per: Grupo Oncoclínicas
Trastuzumab-Emantasin Conjugate is standard for patients with HER2-positive breast cancer and residual disease

Scientific commission

Aline Gonçalves
Aline Gonçalves
Bruno Ferrari
Bruno Ferrari
Carlos Barrios
Carlos Barrios
Daniel Gimenes
Daniel Gimenes

Contributors

Alexandre Boukai
Alexandre Boukai
Daniel Luiz Gimenes
Daniel Luiz Gimenes
Flavia Rocha Paes
Flavia Rocha Paes

This is a scientific newsletter curated by the main medical-scientific content for each specialty and interdisciplinary work between oncology and other areas. Enjoy your reading!

Access the full article of this study
Download
Share
Or share the link
Link copied to your desktop.L